A COMPREHENSION STUDY ON REGULATION OF HERBAL DRUGS IN USA, EUROPEAN UNION AND INDIA
Journal Title: International Journal of Drug Regulatory Affairs - Year 2017, Vol 5, Issue 4
Abstract
The present study reviews the regulations of herbal drugs in the EU, US and India and throws light upon issues related to their clinical trials. Herbal drugs have been used for a long time in different systems of health like Ayurveda, Yunani, Sidha and Homeopathy for treating number of diseases. It is a very difficult to perform clinical study on herbal drugs because these drugs are a complex combination of active ingredients. It is therefore difficult to identify the ingredient which is responsible for the therapeutic effect amongst various ingredients of herbal drugs. The standardization of herbal drugs is also a very difficult task. In spite of all these problems are existing public interest has increased towards herbal drugs in last 2-3 decades because of their long history of treating the disease safely. The laws and regulations for herbal drugs are different in different countries. The WHO has stated that each country should have a system to regulate herbal drugs in their territory. In the EU the committee on herbal medicinal products (HMPC) which part of the EMA was established under regulation (EC) No. 726/2004 and European directive 2004/24/EC in September, 2004. The main duty of HMPC is to evaluate and give authorization for herbal drugs on the basis of their safety and efficacy. In US herbs are classified as dietary supplements after the introduction of the Dietary Supplement Health and Education Act (DSHEA) in1994. In US herbal drugs are categorized into two types, first is OTC herbal drugs and drugs which required NDA approval. In India the Department of AYUSH has made guidelines for quality enhancement of herbal substances. The present study reviews the regulations of herbal drugs in the EU, US and India and throws light upon issues related to their clinical trials.
Authors and Affiliations
Budhwar Vikaas, Sunita Yadav, Manjusha Choudhary, Nitesh K
Keywords
Related Articles
- EP ID EP329065
- DOI 10.22270/ijdra.v5i4.205
- Views 108
- Downloads 0
Regulatory aspects for Biologic product licensing in India
Biologics are the medicinal/ therapeutic/ diagnostic/ preventive preparations composed or derived from living organisms and their spin-off for human use. They include serums, vaccines, antitoxins, blood, antigens and blo...
MEDICAL DEVICES AND THEIR APPROVAL PROCEDURE IN INDIA
Therapeutic treatment based on medical devices is providing technologically advanced solutions for the management of several diseases. Thereby continues to grow in market at tremendous rate. However, these treatments als...
MARKETING AUTHORIZATION APPLICATION (MAA) FOR EUROPE MARKET
This article states requirement of Marketing Authorization Application to get registration of Drug Product to EEA. The procedures for application of marketing authorization are: Centralised procedure, National procedure,...
GLOBAL REGULATORY APPROACH TOWARDS M-HEALTH
The past decade has witnessed rapid advancement in telecommunication and computer technologies. The smart phone is one result of that technological development and has been adopted by hundreds of millions of people world...
PIC/S: TRAINING THE REGULATORS TO REGULATE cGMP COMPLIANCE
PIC/S is an international Organization for implementing cGMP standards in its member countries. The basic objective of PIC/S is to improve and standardize cGMP compliance in member countries. Their aim is to enhance GMP...